Several molecular and genomic biomarkers have been studied to show predictive value for immunotherapy in multiple cancer types, including PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability status (15, 16). This evidence concerns the gene CD274 and neoplasm.